The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1
Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Brognard, J., Clark, A. S., Ni, Y., & Dennis, P. A. (2001) · PubMed · Cited by 987
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., & Stokoe, D. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00493-9 · Cited by 477
Chapter 26. Privileged structures — An update
Patchett, A. A., & Nargund, R. P. (2000) · Annual Reports in Medicinal Chemistry · doi:10.1016/s0065-7743(00)35027-8 · Cited by 302
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.
Page, C., Lin, H., Jin, Y. H., et al. (2000) · PubMed · Cited by 220
Novel PI Analogues Selectively Block Activation of the Pro-survival Serine/Threonine Kinase Akt
Kozikowski, A. P., Sun, H., Brognard, J., & Dennis, P. A. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0285159 · Cited by 198
Zinda, M. J., Johnson, M., Paul, J., Horn, C. L., Konicek, B. W., Lü, Z., Sandusky, G. E., Thomas, J. E., Neubauer, B. L., Lai, M. T., et al. (2001) · PubMed · Cited by 148
Structure-Based Optimization of Novel Azepane Derivatives as PKB Inhibitors
Breitenlechner, C. B., Wegge, T., Berillon, L., Graul, K., Marzenell, K., Friebe, W.-G., Thomas, U., Schumacher, R., Huber, R., Engh, R. A., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0310479 · Cited by 112
Hsu, J.-H., Shi, Y., Hu, L., Fisher, M., Franke, T. F., & Lichtenstein, A. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205194 · Cited by 99
Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma
Graff, J. R. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.1.103 · Cited by 63
Rokhlin, O. W., Guseva, N. V., Taghiyev, A. F., Glover, R. A., & Cohen, M. B. (2002) · The Prostate · doi:10.1002/pros.10074 · Cited by 40
Cited by
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Akt signalling in health and disease
Hers, I., Vincent, E. E., & Tavaré, J. M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.004 · Cited by 1,239
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Metadata
- Authors
- Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., & Duggan, M. E.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 15
- Issue
- 3
- Pages
- 761-764
- ISSN
- 0960-894X (ISSN-L)
- OpenAlex
- W2177206102
- Cited by
- 503
- References
- 14
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.